ATC Group: A10BJ06 Semaglutide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10BJ06 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A10 Drugs used in diabetes
3 A10B Blood glucose lowering drugs, excl. insulins
4 A10BJ Glucagon-like peptide-1 (GLP-1) analogues
5 A10BJ06

Active ingredients in A10BJ06

Active Ingredient Description
Semaglutide

Semaglutide is a GLP-1 receptor agonist. It acts in the same way as GLP-1 (a hormone produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food. This helps with the control of blood glucose levels.

Related product monographs

Title Information Source Document Type  
OZEMPIC Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
RYBELSUS Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
WEGOVY Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

Poland (PL)

Romania (RO)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.